Saga Diagnostics’s technology is based on the analysis of tumor-specific structural variations in DNA from blood samples, in contrast to more traditional methods that focus on individual mutations. This enables highly sensitive detection of residual disease and thereby earlier identification of cancer recurrence, which can be critical for treatment outcomes. 

“Our mission at SAGA is to intercept cancer early when patients are most treatable and curable,” says Roopom Banerjee, Executive Chairman of SAGA. “Foundation Medicine’s commercial scale and innovation accelerates our ability to bring this unique MRD platform to more patients worldwide. We are proud of our team for advancing innovation in the MRD field and commercially launching Pathlight to improve patient outcomes.”

Related article

Careers interview: Lao Saal, CEO, SAGA Diagnostics

Surviving an episode of cancer as a teenager set Lao Saal on a path to seek out better ways to detect, monitor and treat the deadly cells.

The company has achieved several key milestones, including clinical validation of the lead product Pathlight with strong results, commercial launch in the U.S., and Pathlight obtaining Medicare reimbursement for breast cancer, which is a key prerequisite for commercial scaling in the U.S. market. 

When Sciety invested in Saga Diagnostics in 2021, we saw clear potential in the company’s technology to improve how cancer is detected and monitored.

“When Sciety invested in Saga Diagnostics in 2021, we saw clear potential in the company’s technology to improve how cancer is detected and monitored. Since then, the company has established a strong position with clear clinical and commercial relevance in a rapidly growing field. This transaction creates the conditions for the technology to reach more patients faster. The acquisition also marks Sciety’s tenth exit and represents an important milestone for us and our co-investors,” says Andreas Lindblom, Managing Partner at Sciety. 

Following closing, Saga Diagnostics’ platform will be integrated into Foundation Medicine. 

“Pathlight strengthens our comprehensive portfolio of diagnostic solutions and reinforces our commitment to transforming cancer care throughout a patient’s experience,” says Dan Malarek, CEO of Foundation Medicine. “MRD is one of the fastest-growing areas within diagnostics and this technology provides us with a clinically available ultra-sensitive offering. Pathlight has demonstrated strong clinical performance in breast and colorectal cancer, and we look forward to expanding its applicability across other tumor types and indications to improve the lives of even more patients.”

Following closing, Saga Diagnostics’ platform will be integrated into Foundation Medicine.